<DOC>
	<DOCNO>NCT00705224</DOCNO>
	<brief_summary>Naïve patient chronic hepatitis C ( CHC ) genotype treat standard treatment regimen ( pegylated interferon ribavirin ) accord routine clinical practice Russia . The objective study examine influence insulin resistance safety efficacy treatment pegylated interferon ribavirin determine prevalence insulin resistance different population CHC patient .</brief_summary>
	<brief_title>Effect Insulin Resistance Safety Efficacy Pegylated Interferon Ribavirin Treatment HCV ( Study P05562 )</brief_title>
	<detailed_description>consecutive patient sample</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Confirmed diagnosis CHC accord local regulation Naïve Pegylated Interferon ( PEGIFN ) CHC patient No contraindication PEGIFN CHC therapy Negative urine pregnancy test result ( female childbearing potential ) document within 24hour period prior first dose study drug . Additionally , female patient childbearing potential male female partner childbearing potential must use two form effective contraception ( combine ) treatment 6 month treatment end Willingness give write informed consent willingness participate comply study requirement . PEGIFN treatment history Contraindications PEGIFN CHC therapy Females pregnant breastfeed Male partner female pregnant Potentially unreliable participant , judge investigator unsuitable study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>